Latest Insider Transactions at Candel Therapeutics, Inc. (CADL)
This section provides a real-time view of insider transactions for Candel Therapeutics, Inc. (CADL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Candel Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Candel Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 08
2022
|
Seshu Tyagarajan Chief Technology Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$3,000
$1.69 P/Share
|
|
Dec 08
2022
|
Paul Peter Tak Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
3,050
+9.81%
|
$3,050
$1.7 P/Share
|
|
Dec 08
2022
|
Francesca Barone Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
1,238
+31.14%
|
$1,238
$1.61 P/Share
|
|
Dec 08
2022
|
Jason Amello Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,100
+50.0%
|
$3,100
$1.69 P/Share
|
|
Nov 28
2022
|
William Garrett Nichols Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,479
+50.0%
|
-
|
|
Nov 28
2022
|
Francesca Barone Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,877
+49.59%
|
-
|
|
Nov 28
2022
|
Paul Peter Tak Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
195,906
+47.0%
|
-
|
|
Nov 28
2022
|
Jason Amello Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,877
+50.0%
|
-
|
|
Nov 28
2022
|
Seshu Tyagarajan Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
73,684
+50.0%
|
-
|
|
May 06
2022
|
Estuardo Aguilar Cordova > 10% Shareholder |
SELL
Payment of exercise price or tax liability
|
Direct |
54,074
-4.7%
|
$162,222
$3.65 P/Share
|
|
May 06
2022
|
Estuardo Aguilar Cordova > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Direct |
135,183
+10.51%
|
$135,183
$1.46 P/Share
|
|
May 06
2022
|
Laura K. Aguilar > 10% Shareholder |
SELL
Payment of exercise price or tax liability
|
Direct |
68,534
-6.22%
|
$205,602
$3.65 P/Share
|
|
May 06
2022
|
Laura K. Aguilar > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Direct |
171,335
+13.45%
|
$171,335
$1.46 P/Share
|
|
Jul 29
2021
|
Nathan Caffo Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
6,000
+50.0%
|
$48,000
$8.0 P/Share
|
|
Jul 29
2021
|
Laura K. Aguilar > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
56,096
+5.68%
|
-
|
|
Jul 29
2021
|
John J Canepa Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,125
+50.0%
|
$81,000
$8.0 P/Share
|
|
Jul 29
2021
|
Paul B Manning |
BUY
Conversion of derivative security
|
Indirect |
1,232,910
+50.0%
|
-
|
|
Jul 29
2021
|
Paul Peter Tak Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+50.0%
|
$200,000
$8.0 P/Share
|
|
Jul 29
2021
|
Diem Nguyen |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$80,000
$8.0 P/Share
|
|
Jul 29
2021
|
Estuardo Aguilar Cordova > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
162,137
+13.76%
|
-
|
|
Jul 29
2021
|
Christopher Martell |
BUY
Open market or private purchase
|
Indirect |
125,000
+50.0%
|
$1,000,000
$8.0 P/Share
|
|
Jul 29
2021
|
Christopher Martell |
BUY
Conversion of derivative security
|
Indirect |
283,514
+50.0%
|
-
|
|
Jul 29
2021
|
Paul B Manning |
BUY
Open market or private purchase
|
Direct |
20,000
+26.32%
|
$140,000
$7.3 P/Share
|
|
Jul 27
2021
|
Paul B Manning |
BUY
Open market or private purchase
|
Direct |
36,000
+50.0%
|
$252,000
$7.36 P/Share
|